NAPLEX Quiz: Pharmacokinetics And Pharmacodynamics

What this quiz covers

This quiz focuses on Pharmacokinetics And Pharmacodynamics, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Pantoprazole decreases renal clearance of methotrexate, increasing exposure (correct answer)
2. Folic acid inhibits methotrexate absorption, decreasing exposure
3. Naproxen induces methotrexate metabolism, decreasing exposure
4. Methotrexate increases pantoprazole metabolism, decreasing pantoprazole effect

Explanation: This question tests the pharmacokinetic concept of drug-drug interactions affecting renal elimination. The key patient-specific factor is the patient's mild renal impairment with serum creatinine 1.3 mg/dL, potentiating methotrexate accumulation. Pantoprazole decreases renal clearance of methotrexate, increasing exposure is the best choice as PPIs inhibit organic anion transporters, explaining toxicity symptoms and elevated liver enzymes. Folic acid inhibiting absorption is incorrect as it mitigates toxicity; naproxen inducing metabolism is false; methotrexate increasing pantoprazole metabolism does not occur. A transferable clinical pearl is high-dose methotrexate requires leucovorin rescue and hydration to enhance clearance. Decision frameworks include holding MTX if ALT/AST >3x upper limit and monitoring levels with interactors.

Question 2

1. Additive atrioventricular nodal blockade causing bradycardia and hypotension (correct answer)
2. Competitive antagonism at beta receptors causing tachycardia
3. Induction of apixaban metabolism causing bleeding-related hypotension
4. Increased renal clearance of metoprolol causing loss of rate control

Explanation: This question tests the pharmacodynamic concept of additive negative chronotropic effects in rate control. The key patient-specific factor is the patient's atrial fibrillation managed with dual AV nodal blockers, leading to excessive bradycardia. Additive atrioventricular nodal blockade causing bradycardia and hypotension is the best choice as it explains symptoms from combined calcium channel and beta blockade. Competitive antagonism causing tachycardia is opposite; induction of apixaban metabolism causing bleeding is unrelated; increased renal clearance of metoprolol is false. A transferable clinical pearl is avoiding full doses of non-dihydropyridine CCBs with beta-blockers due to syncope risk. Decision frameworks include ECG monitoring and dose titration targeting HR 60-80 bpm in AF.

Question 3

1. Hydrochlorothiazide decreases lithium clearance, increasing lithium concentration (correct answer)
2. Ibuprofen induces lithium metabolism, decreasing lithium concentration
3. Lithium decreases hydrochlorothiazide absorption, lowering lithium concentration
4. Hydrochlorothiazide increases lithium renal secretion, decreasing lithium concentration

Explanation: This question tests the pharmacokinetic concept of drug-drug interactions affecting renal clearance. The key patient-specific factor is the patient's chronic kidney disease with elevated serum creatinine of 1.9 mg/dL, exacerbating lithium accumulation when clearance is further reduced. Hydrochlorothiazide decreases lithium clearance, increasing lithium concentration is the best choice as it explains the toxicity symptoms and elevated level due to thiazide-induced sodium depletion enhancing lithium reabsorption. Ibuprofen inducing lithium metabolism is incorrect as NSAIDs actually decrease lithium clearance; lithium decreasing hydrochlorothiazide absorption lacks evidence; hydrochlorothiazide increasing lithium secretion is opposite to the true interaction. A transferable clinical pearl is that lithium has a narrow therapeutic index, requiring level monitoring with interacting drugs like diuretics or NSAIDs. Decision frameworks include adjusting lithium dose empirically by 25-50% downward when starting thiazides and checking levels within 5-7 days.

Question 4

1. Fluoxetine inhibits CYP2D6, decreasing conversion of tramadol to its active metabolite and reducing analgesia (correct answer)
2. Fluoxetine induces CYP2D6, increasing active metabolite and causing excess analgesia
3. Acetaminophen induces tramadol renal clearance, reducing analgesia
4. Tramadol increases fluoxetine clearance, causing serotonin syndrome

Explanation: This question tests the pharmacokinetic concept of prodrug metabolism via CYP enzymes. The key patient-specific factor is the patient's fluoxetine use, a strong CYP2D6 inhibitor affecting tramadol activation. Fluoxetine inhibits CYP2D6, decreasing conversion of tramadol to its active metabolite and reducing analgesia is the best choice as it explains inadequate pain control from reduced O-desmethyltramadol. Fluoxetine inducing CYP2D6 increasing metabolite is opposite; acetaminophen inducing clearance is minimal; tramadol increasing fluoxetine clearance causing serotonin syndrome is incorrect. A transferable clinical pearl is CYP2D6 poor metabolizers have 20-30% less tramadol efficacy. Decision frameworks include genotyping or avoiding in known inhibitors, preferring non-2D6 opioids.

Question 5

1. Amiodarone induces CYP2C9, decreasing warfarin exposure and increasing INR
2. Amiodarone inhibits CYP2C9, increasing warfarin exposure and increasing INR (correct answer)
3. Atorvastatin induces P-glycoprotein, increasing warfarin clearance and increasing INR
4. Warfarin reduces amiodarone absorption, increasing warfarin effect and increasing INR

Explanation: This question tests understanding of cytochrome P450-mediated drug interactions affecting warfarin pharmacokinetics. The key patient-specific factor is the recent addition of amiodarone to stable warfarin therapy, causing a dramatic INR increase from therapeutic range to 5.2. Option B is correct because amiodarone is a potent inhibitor of multiple CYP enzymes including CYP2C9, which metabolizes the more potent S-warfarin enantiomer, leading to decreased warfarin clearance, increased warfarin exposure, and elevated INR. Option A is incorrect because amiodarone inhibits, not induces, CYP2C9. Option C is wrong because atorvastatin's P-glycoprotein effects are minimal for warfarin, and induction would decrease, not increase, INR. Option D is nonsensical as warfarin doesn't affect amiodarone absorption, and the mechanism described doesn't match the observation. The clinical pearl is that amiodarone-warfarin interaction typically requires empiric warfarin dose reduction of 30-50% when initiating amiodarone, with close INR monitoring for several weeks as amiodarone's long half-life means the interaction develops gradually and persists long after discontinuation.

Question 6

1. Continue enoxaparin 1 mg/kg every 12 hours because platelets are normal
2. Change enoxaparin to 1 mg/kg subcutaneously every 24 hours (correct answer)
3. Increase enoxaparin to 1.5 mg/kg subcutaneously every 12 hours due to high anti-Xa
4. Switch enoxaparin to 40 mg subcutaneously daily (prophylaxis dosing)

Explanation: This question tests the pharmacokinetic concept of renal dose adjustment for anticoagulants to prevent accumulation. The key patient-specific factor is the patient's creatinine clearance of 22 mL/min, reducing enoxaparin clearance and elevating anti-Xa levels. Changing enoxaparin to 1 mg/kg subcutaneously every 24 hours is the best choice as it follows guidelines for CrCl <30 mL/min to minimize bleeding risk while treating DVT. Continuing every 12 hours ignores accumulation; increasing to 1.5 mg/kg is dangerous with high anti-Xa; switching to prophylaxis dosing under-treats thrombosis. A transferable clinical pearl is enoxaparin's half-life doubles in severe renal impairment, necessitating interval extension. Monitoring strategies include anti-Xa levels 4 hours post-dose, targeting 0.5-1.0 IU/mL for once-daily dosing.

Question 7

1. Monitor only serum creatinine weekly because vancomycin efficacy is not concentration-dependent
2. Use area-under-the-curve to minimum inhibitory concentration (AUC/MIC)–guided monitoring and adjust the maintenance dose/interval (correct answer)
3. Target a peak concentration of 80–100 mg/L and ignore troughs
4. Switch to oral vancomycin to reduce systemic exposure and maintain efficacy

Explanation: This question tests understanding of vancomycin pharmacokinetic/pharmacodynamic monitoring in the era of AUC-guided dosing. The key patient-specific factors are obesity (110 kg), renal impairment (SCr 2.0 mg/dL), and supratherapeutic trough level (28 mg/L) indicating excessive exposure and nephrotoxicity risk. Option B is correct because current guidelines recommend AUC/MIC-guided monitoring (target AUC 400-600 mg·h/L assuming MIC=1) rather than trough-only monitoring, as AUC/MIC better predicts both efficacy and toxicity for vancomycin. Option A is incorrect because vancomycin efficacy is concentration-dependent (specifically AUC/MIC dependent), and monitoring only SCr misses the opportunity to optimize dosing. Option C is wrong because peak concentrations are not routinely monitored for vancomycin, and 80-100 mg/L would be extremely toxic. Option D is incorrect because oral vancomycin has minimal systemic absorption and would be ineffective for systemic infections. The clinical pearl is that Bayesian software or two-level pharmacokinetic calculations (using levels at 1-2 hours post-infusion and at trough) can estimate AUC more accurately than trough-only monitoring, reducing nephrotoxicity while maintaining efficacy.

Question 8

1. Continue apixaban 5 mg by mouth twice daily because renal adjustment is not needed when INR is normal
2. Reduce apixaban to 2.5 mg by mouth twice daily (correct answer)
3. Increase apixaban to 10 mg by mouth twice daily due to reduced renal clearance
4. Discontinue apixaban and switch to rivaroxaban 20 mg by mouth once daily

Explanation: This question tests the pharmacokinetic principle of renal dose adjustment for direct oral anticoagulants in patients with multiple risk factors for bleeding. The key patient-specific factors affecting apixaban pharmacokinetics are severe renal impairment (CrCl likely <25 mL/min based on Cockcroft-Gault), advanced age (78 years), and low body weight (52 kg). Option B is correct because apixaban requires dose reduction to 2.5 mg twice daily when patients have at least 2 of 3 criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (this patient meets all three). Option A is incorrect because INR is irrelevant for DOAC dosing and renal adjustment is clearly needed. Option C is dangerously incorrect as increasing the dose would significantly increase bleeding risk in a patient with reduced clearance. Option D is inappropriate because rivaroxaban 20 mg daily would also require dose adjustment in severe renal impairment and unnecessary switching increases risk. The clinical pearl is to remember the "2 of 3" rule for apixaban dose reduction and that DOACs accumulate in renal impairment, requiring careful dose adjustment to balance stroke prevention with bleeding risk.

Question 9

1. Hydrochlorothiazide increases lithium renal clearance by alkalinizing urine
2. Hydrochlorothiazide decreases lithium renal clearance via increased proximal sodium (and lithium) reabsorption (correct answer)
3. Levothyroxine inhibits lithium metabolism, increasing lithium half-life
4. Lithium induces hydrochlorothiazide metabolism, increasing diuresis and lithium levels

Explanation: This question tests understanding of lithium pharmacokinetics and drug interactions affecting renal clearance. The key patient-specific factors are baseline renal impairment, recent thiazide diuretic initiation, hyponatremia, and lithium toxicity symptoms with elevated level. Option B is correct because hydrochlorothiazide decreases lithium renal clearance through a well-established mechanism: thiazides cause mild volume depletion, triggering compensatory increased proximal tubule sodium reabsorption, and since lithium is reabsorbed alongside sodium, this increases lithium reabsorption and decreases its clearance. Option A is incorrect because HCTZ decreases, not increases, lithium clearance, and urine alkalinization isn't the mechanism. Option C is wrong because levothyroxine doesn't significantly affect lithium metabolism. Option D incorrectly suggests lithium affects HCTZ metabolism rather than the reverse. The clinical pearl is that thiazide and loop diuretics significantly increase lithium levels (thiazides more so), requiring 25-50% lithium dose reduction and close monitoring when initiating diuretics; potassium-sparing diuretics like amiloride are safer alternatives if diuresis is needed.

Question 10

1. Excess serotonergic activity due to monoamine oxidase inhibition by linezolid combined with serotonergic antidepressants (correct answer)
2. Reduced serotonin activity due to competitive antagonism at serotonin receptors
3. Increased renal clearance of venlafaxine caused by linezolid leading to withdrawal
4. Additive QT prolongation causing torsades de pointes with primary symptom of diarrhea

Explanation: This question evaluates the pharmacodynamic concept of drug-induced serotonin syndrome through interactions involving serotonergic pathways. The key patient-specific factor is the concurrent use of multiple serotonergic agents, including venlafaxine and trazodone, which increase serotonin levels, compounded by linezolid's effects. Option A is the best choice as linezolid acts as a weak monoamine oxidase inhibitor, leading to excess serotonergic activity when combined with antidepressants, manifesting as agitation, sweating, tremor, diarrhea, fever, and tachycardia. Option B is incorrect because the interaction increases rather than reduces serotonin activity, and there is no competitive antagonism at receptors; option C is suboptimal as linezolid does not significantly affect venlafaxine clearance, and symptoms align with toxicity rather than withdrawal. Option D is wrong because while QT prolongation can occur, it does not primarily cause diarrhea, and torsades de pointes typically presents with arrhythmias, not the observed serotonergic symptoms. A transferable pearl is to screen for serotonergic drug interactions using tools like the Hunter Serotonin Toxicity Criteria. In practice, discontinue the offending agents promptly and provide supportive care, such as benzodiazepines for agitation, while avoiding further serotonergic enhancers.

Question 11

1. Increased protein binding leading to decreased free fraction
2. Decreased protein binding leading to increased free fraction (correct answer)
3. Increased renal clearance of phenytoin due to low albumin
4. Decreased volume of distribution due to hypoalbuminemia

Explanation: This question tests the pharmacokinetic concept of protein binding alterations in drug distribution. The key patient-specific factor is the patient's hypoalbuminemia with albumin 2.0 g/dL, which reduces phenytoin binding sites. Decreased protein binding leading to increased free fraction is the best choice as it explains why the total phenytoin level appears low while free levels may be therapeutic or high, contributing to breakthrough seizures if not adjusted properly. Increased protein binding is incorrect as hypoalbuminemia does the opposite; increased renal clearance due to low albumin is not typical for phenytoin; decreased volume of distribution is unrelated. A transferable clinical pearl is to correct total phenytoin levels for hypoalbuminemia using the equation: corrected = measured / (0.2 * albumin + 0.1). Monitoring strategies include measuring free phenytoin levels in patients with low albumin to guide dosing accurately.

Question 12

1. Continue gabapentin 600 mg three times daily because it is hepatically cleared
2. Reduce gabapentin total daily dose and/or extend dosing interval (e.g., 300 mg once to twice daily) based on creatinine clearance (correct answer)
3. Increase gabapentin to 900 mg three times daily due to tolerance
4. Switch gabapentin to extended-release 1800 mg once daily without renal adjustment

Explanation: This question tests the pharmacokinetic concept of renal drug clearance and dose adjustment in impaired kidney function. The key patient-specific factor is the patient's reduced creatinine clearance of 25 mL/min, indicating moderate-to-severe chronic kidney disease, which impairs the elimination of renally cleared drugs like gabapentin. Option B is the best choice because gabapentin is primarily excreted unchanged by the kidneys, and reducing the dose or extending the interval prevents drug accumulation and minimizes adverse effects such as dizziness and somnolence. Option A is incorrect as gabapentin is not hepatically cleared but renally eliminated, so continuing the current dose would lead to toxicity in renal impairment; option C is suboptimal because increasing the dose would exacerbate side effects without addressing tolerance, which is not indicated here. Option D is wrong because extended-release gabapentin still requires renal dose adjustment, and switching without modification could maintain high exposure. A clinical pearl is that for renally cleared drugs, dose adjustments are guided by creatinine clearance using formulas like Cockcroft-Gault. Always monitor for adverse effects and consider therapeutic drug monitoring when available to optimize dosing in renal impairment.

Question 13

1. Excessive beta-1 blockade causing reduced sinoatrial node automaticity
2. Inhibition of Na+/K+-ATPase leading to increased intracellular calcium and enhanced automaticity (correct answer)
3. Direct antagonism of L-type calcium channels causing atrioventricular block
4. Stimulation of renin release leading to vasoconstriction and visual disturbances

Explanation: This question tests understanding of digoxin's pharmacodynamic mechanism and toxicity manifestations. The key patient-specific factors are elevated digoxin level (2.4 ng/mL), hypokalemia (3.0 mEq/L), and renal impairment affecting digoxin clearance. Option B is correct because digoxin inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium, which triggers the Na+/Ca2+ exchanger to increase intracellular calcium, causing enhanced automaticity and the classic toxicity symptoms of nausea and visual disturbances (xanthopsia - yellow-green vision). Option A is incorrect because while digoxin can cause bradycardia, this is not through beta-blockade but through vagal effects and AV node depression. Option C is wrong because digoxin doesn't directly antagonize L-type calcium channels. Option D is incorrect as digoxin doesn't stimulate renin release or cause vasoconstriction through this mechanism. The clinical pearl is that hypokalemia potentiates digoxin toxicity by increasing digoxin binding to Na+/K+-ATPase, and visual disturbances (especially color vision changes) are pathognomonic for digoxin toxicity. Always check potassium levels and renal function when monitoring digoxin therapy.

Question 14

1. Increase paroxetine to 60 mg daily to overcome reduced CYP2D6 activity
2. Switch to an antidepressant less dependent on CYP2D6 metabolism (e.g., sertraline) and reassess metoprolol dose if bradycardia persists (correct answer)
3. Add carbamazepine to induce CYP2D6 and improve paroxetine response
4. Continue paroxetine unchanged because CYP2D6 status does not affect SSRI exposure

Explanation: This question tests understanding of pharmacogenomics and its impact on drug metabolism and drug-drug interactions. The key patient-specific factors are CYP2D6 poor metabolizer status, inadequate antidepressant response despite adequate dose, and bradycardia suggesting metoprolol accumulation. Option B is correct because paroxetine is extensively metabolized by CYP2D6, so poor metabolizers have reduced clearance leading to higher exposure and increased side effects without necessarily better efficacy; additionally, accumulated paroxetine further inhibits CYP2D6, causing metoprolol accumulation and bradycardia, making switching to a non-CYP2D6 substrate like sertraline the best option. Option A is incorrect and potentially dangerous because increasing the dose would worsen toxicity without improving efficacy. Option C is wrong because carbamazepine cannot induce a genetically deficient enzyme, and adding it would introduce additional drug interactions. Option D is incorrect because CYP2D6 status significantly affects paroxetine and other CYP2D6 substrate exposures. The clinical pearl is that CYP2D6 poor metabolizers (~5-10% of Caucasians) often need alternative antidepressants not primarily metabolized by CYP2D6 (sertraline, citalopram, escitalopram) and careful monitoring when using CYP2D6 substrate medications like metoprolol, codeine, or tamoxifen.

Question 15

1. Continue enoxaparin 80 mg every 12 hours because anti-factor Xa is within goal for treatment
2. Increase enoxaparin to 100 mg every 12 hours because renal impairment lowers drug exposure
3. Change enoxaparin to 80 mg subcutaneously once daily (or use an alternative anticoagulant) due to reduced renal clearance (correct answer)
4. Hold enoxaparin and start warfarin alone immediately without overlap because INR does not need bridging

Explanation: This question tests understanding of low molecular weight heparin pharmacokinetics in renal impairment. The key patient-specific factors are significant renal impairment (CrCl likely ~30 mL/min), elevated anti-Xa level above therapeutic range, and risk of accumulation with twice-daily dosing. Option C is correct because enoxaparin undergoes significant renal clearance, and in severe renal impairment (CrCl <30 mL/min), twice-daily dosing leads to drug accumulation; guidelines recommend either reducing to once-daily dosing (1 mg/kg daily) or considering alternative anticoagulants like unfractionated heparin with aPTT monitoring. Option A is incorrect because the anti-Xa level is above goal and continuing current dosing risks bleeding. Option B is dangerously wrong as increasing the dose would worsen accumulation. Option D is inappropriate because stopping anticoagulation abruptly without overlap in acute DVT risks clot extension, and warfarin requires bridging until therapeutic INR is achieved. The clinical pearl is that anti-Xa monitoring is recommended for LMWH in renal impairment, obesity, or pregnancy; peak levels should be drawn 4 hours post-dose, and accumulation manifests as elevated anti-Xa levels requiring dose adjustment or agent change.

Question 16

1. Increased volume of distribution due to chelation in plasma
2. Decreased oral bioavailability due to chelation in the gastrointestinal tract (correct answer)
3. Decreased hepatic clearance due to CYP inhibition by calcium
4. Increased renal tubular secretion due to urine alkalinization

Explanation: This question tests understanding of chelation interactions affecting fluoroquinolone pharmacokinetics. The key patient-specific factor is concurrent administration of levofloxacin with high-dose calcium carbonate, which can form insoluble chelation complexes. Option B is correct because polyvalent cations (calcium, magnesium, aluminum, iron) bind to fluoroquinolones in the gastrointestinal tract forming insoluble chelate complexes, dramatically reducing oral bioavailability by up to 90% when taken simultaneously. Option A is incorrect because chelation occurs in the GI tract before absorption, not in plasma, and doesn't affect volume of distribution. Option C is wrong because calcium doesn't inhibit CYP enzymes or affect hepatic clearance of levofloxacin. Option D is incorrect as calcium doesn't significantly affect urine pH or renal tubular secretion of fluoroquinolones. The clinical pearl is to separate fluoroquinolone administration from polyvalent cations by at least 2 hours before or 6 hours after the cation-containing product; this interaction is one of the most clinically significant drug-food/supplement interactions that can lead to treatment failure.

Question 17

1. Trimethoprim-sulfamethoxazole decreases methotrexate clearance and adds antifolate effects, increasing toxicity risk (correct answer)
2. Trimethoprim-sulfamethoxazole induces hepatic metabolism of methotrexate, lowering methotrexate exposure
3. Folic acid increases methotrexate absorption, causing acute bone marrow suppression
4. Methotrexate decreases trimethoprim-sulfamethoxazole bioavailability, causing treatment failure and leukopenia

Explanation: This question tests understanding of drug interactions involving antifolate medications and their combined pharmacokinetic and pharmacodynamic effects. The key patient-specific factors are concurrent use of two antifolate drugs (methotrexate and trimethoprim), new-onset cytopenias, and elevated transaminases suggesting methotrexate toxicity. Option A is correct because trimethoprim-sulfamethoxazole has a dual mechanism of increasing methotrexate toxicity: it decreases renal tubular secretion of methotrexate (pharmacokinetic interaction) and adds antifolate effects through dihydrofolate reductase inhibition (pharmacodynamic interaction), leading to bone marrow suppression and mucositis. Option B is incorrect because TMP-SMX inhibits rather than induces methotrexate clearance. Option C is wrong because folic acid supplementation actually helps prevent methotrexate toxicity, not increase it. Option D incorrectly reverses the interaction direction and mechanism. The clinical pearl is that combining antifolate drugs (methotrexate with trimethoprim, pyrimethamine, or probenecid) significantly increases toxicity risk, and alternative antibiotics should be used when possible; if unavoidable, increase folic acid supplementation and monitor blood counts closely.

Question 18

1. Increased fraction unbound due to low albumin, making total concentration appear falsely low (correct answer)
2. Increased renal clearance due to normal serum creatinine, making free concentration falsely low
3. Decreased oral bioavailability due to omeprazole, making free concentration falsely high
4. Increased volume of distribution due to low albumin, making free concentration falsely low

Explanation: This question tests understanding of protein binding and its effect on phenytoin pharmacokinetics and therapeutic drug monitoring. The key patient-specific factor is hypoalbuminemia (albumin 2.0 g/dL), which significantly affects phenytoin's highly protein-bound nature (normally ~90% bound). Option A is correct because low albumin increases the fraction unbound (free) phenytoin, making the total concentration appear falsely low while the pharmacologically active free concentration may actually be therapeutic or even elevated. Option B is incorrect because normal serum creatinine doesn't indicate increased renal clearance, and phenytoin is primarily hepatically metabolized anyway. Option C is wrong because omeprazole doesn't significantly affect phenytoin bioavailability, and this wouldn't make free concentration falsely high. Option D misunderstands the concept - while low albumin does increase volume of distribution for total drug, it's the increased fraction unbound that makes total levels misleading, not the Vd change itself. The clinical pearl is to calculate corrected phenytoin levels using the Sheiner-Tozer equation: Corrected phenytoin = Measured phenytoin / [(0.2 × albumin) + 0.1], or preferably measure free phenytoin levels directly in hypoalbuminemic patients.

Question 19

1. Continue dabigatran 150 mg by mouth twice daily because INR is normal
2. Decrease dabigatran to 75 mg by mouth twice daily (correct answer)
3. Increase dabigatran to 220 mg by mouth twice daily due to amiodarone interaction
4. Switch to dabigatran 150 mg by mouth once daily

Explanation: This question tests the pharmacokinetic concept of renal dose adjustment for drugs primarily eliminated by the kidneys. The key patient-specific factor is the patient's reduced creatinine clearance of 24 mL/min, indicating significant renal impairment that decreases dabigatran elimination. Decreasing dabigatran to 75 mg by mouth twice daily is the best choice because it accounts for reduced renal clearance, minimizing accumulation and bleeding risk while maintaining efficacy for stroke prevention. Continuing 150 mg twice daily is incorrect as it ignores renal impairment, leading to potential overdose; increasing to 220 mg is suboptimal due to the amiodarone interaction actually increasing dabigatran exposure, not requiring a higher dose; switching to 150 mg once daily is inappropriate as it deviates from evidence-based renal dosing guidelines. A transferable clinical pearl is that for renally cleared anticoagulants like dabigatran, use Cockcroft-Gault estimated creatinine clearance to guide dosing adjustments. Monitoring strategies include periodic renal function assessment and bleeding signs to ensure safe anticoagulation.

Question 20

1. Clarithromycin inhibits CYP3A4/P-glycoprotein, increasing colchicine exposure and toxicity risk (correct answer)
2. Atorvastatin induces colchicine metabolism, decreasing colchicine efficacy
3. Colchicine decreases clarithromycin absorption, leading to pneumonia treatment failure
4. Renal impairment increases colchicine hepatic metabolism, lowering colchicine exposure

Explanation: This question tests the pharmacokinetic concept of dual CYP3A4 and P-gp inhibition increasing substrate exposure. The key patient-specific factor is the patient's renal impairment with creatinine clearance 25 mL/min, reducing colchicine elimination. Clarithromycin inhibits CYP3A4/P-glycoprotein, increasing colchicine exposure and toxicity risk is the best choice as it explains severe symptoms from accumulation, especially in CKD. Atorvastatin inducing metabolism is false; colchicine decreasing clarithromycin absorption is incorrect; renal impairment increasing metabolism lowers exposure is wrong. A transferable clinical pearl is colchicine dose reduction to 0.3 mg daily in CrCl <30 with strong inhibitors. Monitoring strategies include assessing for GI/neuromuscular toxicity early in therapy.